Third-generation EGFR-TKI Osimertinib has been successfully shown to improve the survival of advanced and resectable early-stage EGFR-mutated NSCLC based on the results of pivotal clinical trials (e.g., the FLAURA and ADAURA trials) [34,35]. Here, EGFR is linked to non-small cell lung carcinoma.